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Use of ELISpot assay to study HBs-speciﬁc B
cell responses in vaccinated and HBV
infected humans
Chen Tian1, Yuxin Chen2, Yong Liu3, Shixia Wang4, Yang Li1, Guiyang Wang1, Juan Xia1, Xiang-an Zhao 1, Rui Huang1,
Shan Lu4 and Chao Wu1
Abstract
Hepatitis B surface antibody (HBsAb) plays a critical role in protecting against infection of hepatitis B virus (HBV) and
were extensively studied in literature. At the same time, the status of hepatitis B surface antigen (HBs)-speciﬁc B cells in
both vaccinated and HBV infected people received limited attention. In the current study, we adopted a highly speciﬁc
B-cell Enzyme Linked ImmunoSpot (ELISpot) assay to analyze HBs-speciﬁc B cells in various clinical settings: healthy
individuals with the history of HBV vaccination before and after receiving an extra HBV vaccine boost, people
chronically infected with HBV (CHB) in various clinical stages, with or without a particular type anti-viral treatment, or
whether receiving a dose of HBV vaccine. In all of these cases, B-cell ELISpot assay was used effectively in enumerating
the frequency of HBs-speciﬁc B cells. While the focus of the current report was to establish the utility of this assay for
HBV research, a number of interesting observations were made in this pilot study based on the proﬁles and dynamics
of HBs-speciﬁc B cells in various conditions. Such information is useful to guide the future work in designing novel
therapeutic strategies against CHB.
Introduction
Hepatitis B virus (HBV) infection remains a major
health threat in many parts of the world especially in
developing countries including countries with large
human populations such as China1. While the introduc-
tion of a subunit protein-based HBV vaccine has greatly
reduced the rate of new human infections in the last
several decades, the population of people who either were
infected before the introduction of HBV vaccine or mis-
sed the chance of getting vaccinated is still quite large2.
Existing therapies can only partially control the infection
but not cure the diseases3,4. Finding novel treatment
strategies especially an immune therapy is critically
needed.
The signiﬁcance of vaccine-induced antibody (HBsAb)
responses against HBV surface antigen (HBsAg) in pro-
tecting against HBV infection has been well established5,6.
However, HBsAb is basically missing in chronic HBV-
infected patients. How to break body’s immune tolerance
to elicit protective HBsAb that can control the viral
infection is a major challenge in HBV research.
The level of serum HBsAb has been used as the gold
standard in determining the success of HBV vaccination7.
Scientists have also assigned the induction of serum
HBsAb as the biomarker for clinical cure of HBV infec-
tion. However, since most experimental immune thera-
pies have not achieved this goal, there is a great need to
develop alternative biomarkers to detect any early signs of
immune activation against HBV infection. In theory,
HBsAb is produced by hepatitis B surface antigen (HBs)-
speciﬁc B cells and the presence of HBs-speciﬁc memory
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B cells may be an indicator of potential HBsAb
responses. Unfortunately, such tests have not been well
established or widely used to monitor the level of circu-
lating HBs-speciﬁc memory B cells in human peripheral
blood.
In the current study, we investigated the levels of HBs-
speciﬁc B cells in the peripheral blood of 21 HBV vaccine
immunized healthy individuals and 67 patients with dif-
ferent immunological phases of chronic HBV infection.
The relationship between the titer of serum HBsAb and
the level of HBs-speciﬁc B cells was analyzed. Further-
more, the dynamic change of HBs-speciﬁc memory B cells
after either vaccination or antiviral treatment was mon-
itored in this pilot study. Information learned from the
current study would be useful to better understand the
basic immunological mechanisms that are involved in the
induction and maintenance of HBsAb as part of the effort
to develop novel immune therapies against chronic HBV
infection.
Results
HBs-speciﬁc memory B cells in healthy adults with history
of HBV vaccination
A sensitive B-cell ELISpot assay was used in the current
study to detect and enumerate HBs-speciﬁc memory B
cells from human peripheral blood mononuclear cells
(PBMCs) among healthy adult vaccinees. Human PBMCs
were cultured for 5 days in the presence of R848 and IL-2.
The resting memory B cells start secreting detectable level
of speciﬁc antibodies after receiving ex vivo polyclonal
activation8. Among people who had been vaccinated with
HBV vaccine in the past, HBs-speciﬁc memory B cells
would be detected by the HBs-speciﬁc B cell ELISpot
assay. HBsAb secreted by these B cells were captured by
recombinant HBsAg antigen coated on the ELISpot
plates, further demonstrated by colored spots revealed on
the plates following the addition of biotinylated anti-
human IgG antibody and HRP-conjugated streptavidin.
As shown in Fig. 1a, representative B cell ELISpot assay
results revealed HBsAb-secreting B cells from two indi-
viduals (HC9 and HC21) in the healthy control (HC)
group. The frequency of HBsAb-secreting B cells in HC9
was higher than that in HC21, reﬂecting the variation of
HBs-speciﬁc memory B cells in vaccinees. The positive
control wells using PBMCs from the same two individuals
showed much higher frequency of non-speciﬁc total IgG-
secreting B cells when anti-human IgG was used as the
capture reagent. Wells without any capturing reagent
were used as the negative controls (Fig. 1a).
Among 21 individuals included in the HC group, 17 of
them (80.95%) had positive HBsAb-secreting B cells,
despite they all had reported history of HBV vaccination
at least 2 years ago. This result ﬁt the reports that about
20% of vaccinated people were non-responders9–11. The
value of HBsAb-secreting B-cell measurement was further
conﬁrmed based on the association between serological
HBsAb level and frequency of HBsAb-secreting B cells.
Vaccinees with >200mIU/mL of serum HBsAb had a
signiﬁcantly higher level of HBsAb-secreting B cells
compared to those with <200mIU/mL of serum HBsAb
(98.33± 10.89 vs.18.4± 6.81 per 106 PBMCs; p< 0.0001;
Fig. 1b). A strong correlation was observed between
HBsAb level and the frequency of HBsAb-secreting B cells
among vaccinees (p< 0.0001, r= 0.909; Fig. 1c). In the
latter analysis, only data from 15 healthy individuals were
included because the rest of people had serum HBsAb
level which was too high to be quantiﬁed by the particular
measurement process used in the study. Therefore, at
least within the optimal measurement range, the level of
blood HBsAb was proportional to the frequency of cir-
culating HBs-speciﬁc memory B cells among healthy
vaccinated people.
Fig. 1 HBs-speciﬁc B cells in health volunteers. a Representative B-cell ELISpot readouts from healthy volunteers HC9 and HC21. 100,000 cells were
added in HBsAg-coated wells (up panel) and negative wells (middle panel) and 5000 cells were added in IgG coated wells (bottom panel). b The
frequency of HBs-speciﬁc memory B cells was signiﬁcantly reduced in groups with lower level of serum HBsAb (<200mIU/ml), compared to the
groups with higher serum HBsAb ( > 200mIU/ml). c A strong correlation between the serological HBsAb and the number of memory B cell was
detected in HCs. SFC, spot-forming cells. Each dot represents one individual
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Dynamic change of HBs-speciﬁc B cells following boosting
vaccination
To further evaluate whether HBs-speciﬁc B-cell ELISpot
assay can be used to monitor the short-term immune
response after vaccination, 7 out of 21 healthy individuals
who received three doses of HBV vaccines during their
childhood but had low level HBsAb responses in our
study agreed to receive one additional HBV vaccine boost.
Both the titer of HBsAb responses and the frequency of
HBsAb-secreting B cells were measured on day 0 (prior to
immunization) and at days 7 and 28 post the HBV vaccine
boost. As expected, all subjects had substantial increase in
serum HBsAb titers at day 7 post vaccine boost and
HBsAb titers went even higher at day 28 post boost
(Fig. 2a). As illustrated by one representative B-cell ELI-
Spot result from the healthy volunteer HC18, a pro-
nounced elevation of HBsAb-secreting B cells was
observed at day 7 post the boost (Fig. 2b), which is mainly
contributed by the response of plasmablast B-cell popu-
lation typical with the peak time around 7 days after the
boosting immunization in a previously vaccinated host12.
The HBsAb-secreting B-cell levels came down quite
quickly to a lower level at day 28 post the boost but
remained elevated, which represent the further expansion
of HBs-speciﬁc memory B-cell population (Fig. 2b). While
the elevation of HBsAb-secreting B cells varied somewhat
among these seven individuals, the group average
demonstrated the same pattern of a quick elevation at day
7 and maintained at a lower but still elevated level at day
28 post boost (Fig. 2c).
The above results conﬁrmed that a HBV vaccine could
elevate the HBsAb secreting B cells with pronounced peak
at day 7, and boost antibody titers with a later peak time.
In a previously immunized healthy population, each boost
immunization should expand both plasmablast/plasma
cells and the memory B cells. Plasmablast/plasma cells are
directly responsible for the quick production of anti-
bodies. Increase of memory B cells on the other hand will
expand the pool of HBs-speciﬁc IgG-secreting B cells for
later even more pronounced antibody responses. In our
study, B-cell ELISpot assay is accurate and sensitive to
quantitatively demonstrate the dynamic changes of HBs-
speciﬁc B cells in healthy individuals.
Detection of HBs-speciﬁc B cells in chronic HBV-infected
patients
We next tried to determine whether our assay was
sensitive to detect any HBs-speciﬁc B cells present in the
peripheral blood of chronic hepatitis B infected (CHB)
patients. To our surprise, HBsAb-secreting B cells could
be easily detected in certain CHB patients as shown by the
representative data from two CHB patients in Fig. 3a. In
our study, 16 (31.4%) out of 51 CHB patients had positive
HBsAb-secreting B cells as revealed by B-cell ELISpot
assay. Further investigation found that some of these
patients also had detectable HBsAb in their sera, and
there was a general relationship between the serum level
Fig. 2 HBs-speciﬁc B cells in healthy volunteers post immunization. a Serum HBsAb titers increased persistently in all immunized healthy
subjects at day 7 and day 28 post HBV vaccine boost. b Representative B-cell ELISpot readouts (HC18), who had already ﬁnished HBV vaccine
immunization 2 years ago, at day 0 (top), day 7 (middle) and day 28 (bottom) after HBV vaccine boost were shown. c HBs-speciﬁc B-cell responses
were measured either at day 7 or day 28 after boost. *P < 0.05
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of HBsAb and the frequency of HBs-speciﬁc B cells in
CHB patients. CHB patients with relatively high level of
HBsAb (>1mIU/mL) had signiﬁcantly elevated level of
HBs-speciﬁc B cells than CHB patients with low HBsAb
level (<1mIU/mL) (14.58± 6.61 vs.4.69± 2.24 per 106
PBMCs) (p< 0.05) (Fig. 3b). However, we did not ﬁnd a
linear correlation between serum HBsAb and the fre-
quency of HBs-speciﬁc B cells among CHB patients (p=
0.811, r= 0.135) (data not shown). This ﬁnding may
reﬂect different B cell dynamics in CHB patients who
receive constant re-stimulation by the viral antigens.
More signiﬁcantly, the frequency of HBsAb-secreting B
cells was signiﬁcantly lower in CHB patients than in
healthy vaccinated individuals (7.4± 2.5 vs 52.66± 10.64
per 106 PBMCs) (p< 0.0001, Fig. 3c).
Once we observed the presence of HBs-speciﬁc B cells
in the peripheral blood of CHB patients, we next studied
whether such cells were only present in certain subgroups
of HBV patients during their natural history of infection.
According to 2012 EASL guidelines13, the three major
phases among CHB infection are immune tolerant phase
(IT), immune reactive HBeAg-positive phase (IA) and
inactive HBV carrier state (IC). IT phase is characterized
by a high level of HBV replication whereas there is no or
only mild liver necroinﬂammation. IA phase has relatively
low level of replication compared to IT stage, but has an
increased or ﬂuctuating level of aminotransferase, mod-
erate or severe liver necroinﬂammation and more rapid
progression of ﬁbrosis. IC phase is characterized by low or
undetectable serum HBV DNA along with normal serum
aminotransferase. In our study a total of 51 patients from
these three phases were included (Table 1).
Fig. 3 HBs-speciﬁc B cells in chronic hepatitis B (CHB) patients. a RepresentativeELISpot data from two CHB patients P27 and P23 were shown.
Each condition was performed in duplicates. b Patients with lower level of serum HBsAb (<1 mIU/ml) had relatively fewer HBsAg-speciﬁc B cells,
compared to those patients with higher level of serum HBsAb (>1mIU/mL). c The numbers of HBs-speciﬁc B cells among 106 PBMC population were
shown in each individual from HC group and CHB patient group
Table 1 Clinical characteristics of CHB patients and HCs
in the study
Group IT IA IC HC
No. of Cases 13 17 21 21
Gender (M/F) 10/3 11/6 17/4 8/13
Age (years) 31(27–33) 28(26–34) 36(30–39) 27(25–34)
HBsAg + + + −
HBeAg + + − −
ALT (U/L) 32.9 104 27.1 18.9
(23.95–45.5) (73.5–150) (19.7–37.1) (9.475–33.8)
HBV DNA 7.528 6.812 ND ND
(log10 IU/ml) (7.33–7.826) (5.318–7.61)
HC healthy controls, IA immune reactive HBeAg-positive phase, IC Inactive HBV
carrier state, IT Immune tolerant phase, ND not detectable, ALT alanine
transaminase. Data are shown as median and range
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Based on the B-cell ELISpot assay, the percentage of
positive HBsAb-secreting B cells in IT phase of HBV
patients was 30.8% (4 out of 13 IT patients), 47.1% (8 out
of 17 IA patients), and 19.1% (4 out of 21 IC patients;
Fig. 4a), indicating that HBsAb-secreting cells were pre-
sent in all three subtypes of HBV patients but it appeared
that less patients in IC phase had HBsAb-secreting B cells
although the study sample size was too small to draw a
conclusion. Further analysis showed that patients in IT
group had an average of 8.75± 6.46 HBsAb-secreting B
cells per 106 PBMCs, patients in IA group had an average
of 11.15± 4.67 HBsAb-secreting B cells per 106 PBMCs
and patients in IC group had an average of 3.5± 2.41
HBsAb-secreting B cells per 106 PBMCs, also indicating
less HBsAb-secreting B cells in IC group patients. All
three groups had signiﬁcantly lower frequency of HBsAb-
secreting B cells than in healthy subjects (Fig. 4b).
HBs-speciﬁc B-cell responses in HBV patients receiving one
dose HBV vaccine
There were off-label uses of HBV vaccines in an attempt
to induce HBsAb in certain HBV patients but no pub-
lished report to conﬁrm the clinical beneﬁts of such
practice. In the current study, we investigated whether
one does of regular HBV vaccine may induce or expand
HBs-speciﬁc B-cell responses in CHB patients, in addition
to the traditional practice of monitoring the HBsAb
responses.
Since previous literature suggested that most CHB
patients undergoing HBsAb seroconversion had low level
of HBsAg, and immune responses could be impaired with
presence of large amount of serological HBsAg14–16, we
hypothesized that CHB patients with undetectable HBV
DNA and low level of serum HBsAg might be more
capable to respond to HBV vaccination. Twelve CHB
patients were recruited in this pilot study. Among them,
four patients (33.33%) had serum HBsAg less than 100
IU/ml which was achieved spontaneously and treatment
naive, and the other eight patients (66.67%) had received
long-term anti-viral treatment and achieved good viral
load suppression. All of twelve patients received one-time
immunization of HBV vaccine Engerix B®. Their HBs-
speciﬁc B-cell responses were monitored by B-cell ELI-
Spot assay on day 0 (prior to immunization) and at day 7
and 28 after the immunization.
Low level of HBs-speciﬁc B cells was detected in several
patients even at day 0, and one-time HBV vaccine did not
signiﬁcantly increase the frequency of HBsAb secreting B
cells as shown in patient VP6 (Fig. 5a). HBsAb testing
showed below 10mIU/mL in these CHB patients before
vaccination and the HBsAb titers had little change after
one dose HBV vaccination (Fig. 5b). The HBsAb-secreting
B cells numbers went up ﬁrst at Day 7, then dropped at
day 28 after the vaccination to a level similar to day 0
(Fig. 5c). Such a pattern was different from that for
healthy adults after the HBV vaccine boost (Fig. 2).
Without prior history of HBV vaccination, one-time
immunization in CHB patients may only prime the
immune system to have HBs-speciﬁc B-cell expansion but
failed to increase the production of HBsAb. The exact
mechanism is not clear but the circulating HBsAg as part
of active HBV infection may have some inhibitory effect.
This is very different from healthy people with history of
vaccination who have highly responsive HBs-speciﬁc
memory B cells and can easily respond to an additional
vaccine boost with higher levels of HBsAb and HBs-
speciﬁc B-cell responses.
HBs-speciﬁc B-cell responses in HBV patients receiving
Pegylated interferon (PEG-IFN) treatment
Based on the above observation, we further tested the
HBs-speciﬁc B-cell responses in patients who have
received PEG-IFN immune treatment and some of them
had very low HBsAg in circulation before the test. PEG-
IFN is a long-acting IFN which modulates body’s immune
responses with the potential of inducing sustained off-
Fig. 4 HBs-speciﬁc B cells in CHB patients. a The positive rates of HBs-speciﬁc B cells in immune tolerant (IT), immune reactive HBeAg-positive (IA),
and inactive HBV carrier (IC) phases were expressed as a percentage. b The frequencies of HBsAb-SFCs among three CHB phases were displayed.
**p < 0.01
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treatment response and HBsAg clearance17–19. To exam-
ine if PEG-IFN treatment can impact the kinetics of
HBsAb-secreting B cells, B cell ELISpot assay was
conducted in 4 HBV patients before and after PEG-IFN
treatment (Fig. 6a). Three patients (patient 1 to 3) were
treated with nucleos(t)ide analogs for months to years,
Fig. 5 HBV Vaccine-elicited memory B-cell response in CHB patients. a Representative B-cell ELISpot readouts (patient VP6) at days 0 (left), 7
(middle) and 28 (right) after booster. b Serum HBsAb titers and (c) HBs-speciﬁc B cells were quantitatively measured from 12 CHB patients at days 0, 7,
and 28 after receiving the HBV vaccination
Fig. 6 HBs-Speciﬁc memory B cell response with PEG-IFN treatment. a Therapeutic regimens of four CHB patients. Patient 1, 2, and 3 had
combination of PEG-IFN with nucleoside analogs while patient 4 had PEG-IFN treatment alone. b Serum HBsAg levels, HBs-speciﬁc B cells and serum
HBsAb titers before (white column) and after (black column) PEG-IFN treatment of these 4 patients were displayed. ETV entecavir, ADV adefovir
dipivoxil, LAM lamivudine, TDF tenofovir
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and then had an add-on PEG-IFN therapy for 48, 24 and
12 weeks, respectively. The fourth patient was given PEG-
IFN alone for 48 weeks.
Two patients (patients 2 and 4) showed detectable
HBsAb-secreting B-cell responses after either 24-week or
48-week treatment with PEG-IFN (0 vs. 11.6 or 0 vs. 30
per 106 PBMCs, respectively). Patient 2 showed detectable
HBs-secreting B cell responses and correlated well with
the signiﬁcant increase of serum HBsAb. Patient 4 showed
higher detectable HBs-secreting B-cell responses after
PEG-IFN treatment, but no increase of serum HBsAb at
the time of test, but it is not clear whether there will be
delayed HBsAb responses. On the other hand, there was
no improvement on the detection of HBsAb-secreting B
cells for the other two patients and none of them had
detectable HBsAb responses (Fig. 6b). Interestingly, both
patients who had good HBs-speciﬁc B-cell responses had
very low serum HBsAg levels (Fig. 6b), further supporting
the idea that circulating HBsAg may have inhibitory effect
to the induction of HBsAb.
Discussion
It is well established in literature that HBsAb can pro-
vide long-term protection in a general healthy popula-
tion20–22. The protective role of HBsAb in clearance of
circulating HBsAg and suppression of HBV replication
was also reported. For example, the combination of HBV
vaccine and hepatitis B immunoglobulin (HBIG) given
within 12 h of birth to neonates born from HBV-infected
mothers signiﬁcantly diminished the rate of perinatal
transmission of HBV13. HBV-infected patients receiving
liver transplantation had a more rapid clearance of serum
HBsAg, if the donor previously generated robust HBsAb
responses23,24.
Therefore, the disappearance of HBsAg and the induc-
tion of protective HBsAb responses are considered as an
optimal treatment endpoint, termed as ‘functional cure’.
However, only very small percentage of CHB patients
cleared HBsAg, with or without treatment13,25. A pro-
mising clinical observation is that, for patients who
experienced the complete loss of HBsAg after decades of
anti-viral treatment, they could generate decent levels of
HBsAb26, indicating that B cells from HBV patients may
still maintain the potential to produce HBsAb. In contrast,
it was reported that diminished HBsAg-speciﬁc B-cell
responses were correlated with HBV persistence27. The
main challenge is how to identify those CHB patients who
may be more likely than the others to develop HBsAb and
clear HBsAg, and what therapeutic strategies can be
developed to take advantage of such mechanism to
achieve a good clinical outcome.
It was recognized that tracking HBs-speciﬁc memory B
cells by ELISpot assay was more reliable than measure-
ment of HBsAb secreted in supernatants of cultured B
cells by an ELISA22. Indeed, since such assay was descri-
bed as early as in 1983 (ref. 28), B-cell ELISpot assay has
been used effectively in studying various viral infections
including hepatitis C virus29, inﬂuenza virus30, human
cytomegalovirus31, Epstein-Barr virus32, and dengue
virus33. These studies provided unique information which
otherwise would not be learned from the traditional
antibody studies.
B-cell ELISpot method was also used to study the
impact of HBV vaccination in normal people22 but very
few such studies were done in HBV infected patients. One
issue is the quality requirements for such assays to be
sensitive and speciﬁc enough to measure the low level
HBs-speciﬁc B cells in HBV infected people. In the cur-
rent study, we followed the successful technical approach
used in a recent report on HIV-speciﬁc B cells respon-
ses34, and adopted the same approach to the study of
HBV-speciﬁc B-cell responses in both normal healthy and
infected people.
In this pilot study, HBs-speciﬁc B-cell responses were
measured in four clinical settings. First, we demonstrated
the utility of B cell ELISpot assay to detect and quantify
HBs-speciﬁc memory B cells in people previously vac-
cinated by HBV vaccines. The levels of B cell responses
were proportional to the serum HBsAb. This ﬁnding was
not unexpected but it also pointed the possibility of
using HBs-speciﬁc B-cell ELISpot to monitor the
immunogenicity of HBV vaccines especially for those
‘non-responders’. In this part of study, people were
recruited many years after the primary vaccination
course, and the effective vaccines generated protective
HBs-speciﬁc B-cell memory. The ELISpot readout
mainly showed the memory B cells after in vitro stimu-
lation. It will be interesting to conduct the similar studies
shortly after the end of 3-dose immunization series as
well as the long-term follow-up on the dynamics of HBs-
speciﬁc B cells in people who completed the HBV
immunizations.
Second, the effects of one-time boosting with HBV
vaccine to previously immunized healthy people were
studied. The HBsAb and HBs-speciﬁc B cells with re-
exposure of HBV vaccine took different responding pat-
terns. Over the period of 28 days after the boost, the
serum HBsAb went up steadily due to the continuous
production of antibodies after boosting the previously
immunized hosts. The HBs-speciﬁc memory B cells pro-
liferate robustly in response to HBsAg re-exposure and
promote the generation of plasma cells, which produce
the circulating antibodies35. On the other hand, HBs-
speciﬁc B cells had a prominent peak around 7 days but
quickly dropped to a level still higher than the baseline
level. This indicated that activated B cells differentiate
into short-lived plasmablasts whose number peaks at days
6 or 7, in addition to the memory B cells. By day 28 only
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memory B cells became the main circulating HBs-speciﬁc
B cells.
Third, we did observe very low level but clearly positive
HBs-speciﬁc B cells in CHB patients at various immu-
nological phases which were different from a previous
study showing the deﬁciency of HBs-speciﬁc B cells in
CHB patients27. The discrepancy might be derived from
the experimental details in previous B-cell ELISpot assay.
For example, Phytolacca americana pokeweed mitogen
was used for polyclonal stimulation of PBMCs36, which
may not be as potent as the combination of R848 and IL-
2. Furthermore, the stimulation time (3 days) might not
be sufﬁcient, while in our study, PBMCs were stimulated
for 5 days. Our optimized B-cell ELISpot approach used in
the current study was successful in evaluating HBs-
speciﬁc memory responses as that reported for HIV vac-
cine studies using the similar approach34. By using this
optimized assay, we found that the levels of HBs-speciﬁc
memory B cells in IA phase were much higher than in the
IC phase of CHB patients. A larger sample size is needed
to further conﬁrm that the frequency of HBs-speciﬁc B
cells is higher in IA than IC phases.
Finally, we studied whether immune therapies can boost
the level of HBs-speciﬁc B-cell responses. When CHB
patients received one dose HBV vaccine, there was basi-
cally no clear induction of HBs-antibodies. In these
patients, the frequency of HBs-speciﬁc B cells was also
maintained at very low level, despite a slightly higher level
at day 7 with a high standard deviation. Therefore,
receiving one-dose HBV vaccine in CHB patients is not
likely to bring desired immunological responses. Future
studies can be conducted with additional doses of vaccine
and the B-cell ELISpot assay can be used to monitor the
immune responses.
In our study, we also provide the ﬁrst evidence that
PEG-IFN, a non-antigen-speciﬁc immune treatment
induced HBs-speciﬁc memory B-cell responses in at least
two patients. Potent antiviral drugs could efﬁciently sup-
press viral replication via inhibiting the reverse tran-
scriptase or HBV polymerase; while PEG-IFN modulated
the immune-mediated control of HBV infection, provid-
ing an opportunity to achieve HBsAg clearance. Previous
studies reported that 30% of patients treated with PEG-
IFN for 48 weeks experienced HBeAg seroconversion,
whereas only 3–7% fully cleared HBsAg in other clinical
trials37–39. In one hospital-based study in Asia, PEG-IFN
was added after 24 weeks of entecavir therapy and
improved the response rate, as demonstrated by HBeAg
loss and declines in HBV DNA40,41. Further, high rates of
HBsAg clearance and seroconversion could be achieved
by PEG-IFN-based treatments even in inactive HBsAg
carriers among whom treatment was not traditionally
recommended17. In current study, we demonstrated that
PEG-IFN treatment was able to expand the HBs-speciﬁc B
cells in CHB patients. Future studies with much large
study cohorts should recruit CHB patients with sup-
pressed HBsAg who will then receive PEG-IFN treatment
and the development of HBs-speciﬁc B-cell responses will
be monitored in addition to the study of HBsAb. In our
current study, one patient developed HBs-speciﬁc B cell
response but no obvious HBsAb responses which may
indicate the later development of antibodies than the B-
cell responses. If it is true, then the HBs-speciﬁc B-cell
responses can be used as an early indicator of good
therapeutic responses.
In summary, the current report described the useful
applications of a sensitive and speciﬁc B-cell ELISpot
assay to study the immune responses in healthy and
HBV-infected patients. Findings in this pilot study also
pointed to several potential directions to test the effects
of antigen-speciﬁc and non-antigen-speciﬁc immune
therapy strategies when the HBs-speciﬁc B-cell ELISpot
is used to follow the clinical outcome of such immune
interventions. At least, ELISpot assay can be further
improved by including phenotypic cell markers thus it
can provide additional information to understand the
immunological mechanisms that are involved in the
induction and maintenance of HBsAb in the various
clinical settings.
Materials and methods
Study participants
The healthy control group (HC) included 21 adult
volunteers who completed the standard HBV vaccine
immunization (three doses) at their childhood. Seven of
them received one-time boost of HBV vaccine Engerix B
in the current study.
A total of 67 HBV-infected patients were enrolled in
this study. Patients with end-stage liver insufﬁciency,
autoimmune disorders, or malignancies were excluded
from the study. Patients who were positive for antibodies
against other types of hepatitis or human immunodeﬁ-
ciency virus were also excluded. These patients were
included in several studies. In one study, 51 HBV patients
who did not receive any antiviral treatment (‘treatment
naïve’) were further divided into three subgroups: 13 in
immune tolerant (IT) subgroup, 17 in immune reactive
HBeAg-positive (IA) subgroup, and 21 in inactive HBV
carrier (IC) subgroup based on the 2012 clinical guide-
lines prepared by the European Association For The
Study Of The Liver (EASL)13. In another study, 12 CHB
patients who had relatively low HBsAg level (<100 IU/
mL) received one-time HBV vaccine Engerix B immuni-
zation. The ﬁnal study included four chronic HBV
patients who received either PEG-IFN treatment alone
(one patient) or in combination with nucleoside analog
drugs (three patients).
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All participants were provided with a written informed
consent for blood sampling and HBV vaccination under a
human clinical study protocol approved by Medical Ethics
Committee of Nanjing Drum Tower Hospital.
PBMC isolation
PBMCs were prepared from 10mL fresh heparinized
study subjects’ peripheral blood specimens by density
gradient centrifugation using a Ficoll cushion. Brieﬂy,
blood diluted with phosphate-buffered saline (PBS) was
added into Ficoll and 10× 106 PBMCs were isolated after
centrifugation. Aliquots of PBMCs were stored using
Cryostar Freezing Kit (Cat#: UH-M1002-050, DAKEWE,
Beijing, China) in liquid nitrogen until being used for B-
cell ELISpot assay.
PBMC culture and B-cell stimulation
After thawing, PBMCs were resuspended in RPMI 1640
medium (Gibco, Invitrogen, Paisley, UK) at 2× 106
PBMCs/mL supplemented with streptomycin, glutamine,
and 10% fetal bovine serum (FBS). To effectively stimulate
B cells, 1 μg/mL R848 and 10 ng/mL recombinant human
(rh) IL-2 (Mabtech, Nacka Strand, Sweden) were added.
Cells were subsequently incubated for ﬁve days at 37 °C,
5% CO2, followed by washing with RPMI 1640 medium
prior to plating.
B-cell ELISpot assay
Sterile 96-well Multiscreen-IP ﬁlter plates with a PVDF
membrane (Millipore Corp, Bedford, MA, USA) were
coated with either anti-human IgG (15 μg/mL, Mabtech,
Nacka Strand, Sweden) or recombinant HBsAg (10 μg/
mL) overnight at 4℃. Numbers of total IgG+ secreting
cells were determined by wells coated with capture anti-
human IgG, while numbers of HBsAb secreting B cells
were examined by wells coated with HBsAg. Wells with
no coating were used as negative controls. Plates were
washed with sterile PBS and blocked with RPMI-1640
medium/10%FBS for 2 h at room temperature. Serially
diluted pre-activated cells were added at 5000 or 2500
cells/well for IgG coated wells, 100,000 cells/well for no
coat wells, and 100,000, 200,000, or, 400,000 cells/well for
HBsAg-coated wells. The culture plates were incubated
for 18 h at 37 °C, 5% CO2. Each condition was performed
in duplicates. Frequency of antibody-secreting cells was
measured after washing with PBS and incubation with
biotin-labeled anti-IgG mAb (Mabtech, cat#3850-2 H,
Sweden) and horseradish peroxidase (HRP)-conjugated
streptavidin (Mabtech, Nacka Strand, Sweden). An auto-
mated ELISpot image analyzer (Cellular Technology
Limited, Hongkong, China) was used to analyze and count
the spots. Frequency of HBsAb-secreting B cells per well
was calculated by subtracting background values from
negative control wells.
PEG-IFN treatment
Managed as part of the regular clinical treatment by
infectious disease specialists, 4 HBV patients were treated
with PEG-IFNα-2a (Pegasys, Roche, USA). Three of them
received the add-on PEG-IFN after months or years of
treatment with nucleos(t)ide analogs, while the 4th
patient did not have previous history of HBV treatment
and received PEG-IFN treatment alone during the course
of current study. The blood samples were collected before
and after the PEG-IFN treatment.
HBV vaccine administration
Certain groups of subjects received one-time intra-
muscular injection of HBV vaccine Engerix B® (20 µg
HBsAg protein, GlaxoSmithKline, Brentford, UK) during
the study period. Heparinized blood (10 ml) was obtained
on day 0 (prior to immunization), at day 7 and day 28 post
immunization for serum antibody and B-cell ELISpot
analyses.
Assessments of HBV serologic biomarkers
Routine HBV serologic markers (HBsAg, HBsAb,
HBeAg, HBeAb, and HBcAb) were determined using
Architect-i2000 system (Abbott Laboratories, USA). The
quantitative determinations of biomarkers were con-
sidered positive according to the criteria set by the
manufacturer.
Statistical analysis
All the above experiments were done in triplicate. Final
data were analyzed statistically if indicated by using the
SPSS 22.0 software. Most data were presented in form of
mean± s.e.m. Results with p-value <0.05 were considered
to be statistically signiﬁcant.
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